Performance and Safety of Class IIb MD Celegyn® in VVA

Vulvovaginal Atrophy Clinical Trial

Official title:

Evaluation of Performance and Safety of the CE Marked Medical Device Class IIb Celegyn® in Vulvovaginal Atrophy (VVA): a Randomised, Double-blind, Parallel Groups, Multicentric, Placebo-Controlled, Prospective Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03823560
• Other study ID #: CeleMD01
• Status: Recruiting
• Phase: N/A
• Start date: September 24, 2019
• Est. completion date: September 2021

Study information

• Verified date: January 2021
• Source: Nathura S.p.A
• Contact: Antonio Bertolino, PhD
• Phone: +390249530065
• Email: antonio.bertolino[@]evidilya.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is primarily to investigate the performance of Celegyn®, a hyaluronic acid-based vaginal cream (CE marked 0546 medical device), enriched with plant-based ingredients, in comparison with placebo, in promoting vaginal health in adult woman reporting symptoms of vulvovaginal atrophy - VVA (or atrophic vulvovaginitis)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 96
• Est. completion date: September 2021
• Est. primary completion date: September 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Female patients aged between 18 and 65 years.

2. Patients reporting vulvovaginal dryness associated with spontaneous pain and / or dyspareunia (minimum score of 30 on a 100 mm Visual Analogue Scale for both symptoms referable to vulvovaginal atrophy: dryness and spontaneous pain and / or dyspareunia).

3. Patients sexually active (i.e. women who currently have intercourse or other sexual activity (masturbation, etc) at least once a month (with or without a partner), or who had intercourse or other sexual activity at least once a month in the past, but later decreased sexual activity due to excessive pain or vaginal dryness. Dyspareunia is defined (2nd International Consultation on Sexual Medicine) as "persistent or recurrent pain with attempted or complete vaginal entry and/or penile vaginal intercourse" that is not the result of other abnormalities).

4. Patients agreeing not to use lubricants or other topically applied vaginal products during the study and not to modify their personal hygiene products.

5. Patients of childbearing potential following a reliable (according to investigator's opinion) non-hormonal contraception therapy.

6. Patients presenting body mass index between 18.5 and 29.9 kg/m2.

7. Patients with normal Papanicolaou test results (including inflammatory changes) within the past 12 months after specimen collection.

8. Willingness to participate in the study and to sign an informed consent form.

9. No past or present narcotic addiction or alcoholism.

Exclusion Criteria:

1. Patients presenting vulvar or vaginal pathology other than vulvovaginal atrophy.

2. Patients pregnant or breastfeeding.

3. Patients presenting undiagnosed abnormal genital bleeding.

4. Patients presenting endometrial pathology, such as hyperplasia (endometriosis) or endometrial polyps, cancer, palpable fibroids or grade 2 uterine prolapse (when the cervix reaches the labia minora) on gynaecologic examination.

5. Patients presenting coagulation disorders or on anticoagulant drug therapy (except clopidogrel or acetylsalicylic acid).

6. Patients diagnosed with clinically significant metabolic or endocrine disease or diabetes mellitus uncontrolled by medication.

7. Patients diagnosed with hypertension and in treatment with antihypertensive medications.

8. Patients diagnosed with severe renal and/or hepatic insufficiency.

9. Patients who have changed or started systemic oestrogen - progestin or hormone therapy in the 3 months prior to inclusion (including contraceptive therapy (pill) or Substitutive Hormonal Therapy (SHT)).

10. Patients on systemic chronic oestrogen - progestin therapy (including contraceptive therapy (pill) or Substitutive Hormonal Therapy (SHT)).

11. Patients in treatment with the following systemic drug: nonsteroidal anti-inflammatory drugs, antihistamines, corticosteroids in the 2 weeks prior to inclusion, immunosuppressants in the 3 months prior to inclusion, venotonic or diuretic agents in the month prior to inclusion.

12. Patients using topic oestrogen - progestin or hormonal therapy, in the week prior to inclusion.

13. Patients in treatment with topically applied vaginal products, including medications to promote healing, in the week prior to inclusion.

14. Patients that participated in any other clinical trial during the last month or participating in any clinical trial while participating in this trial.

15. Patients reporting allergy or intolerance to any component of test product, placebo or rescue product.

16. Smoking patients.

17. Patients who in the opinion of the principal investigator are at risk of non-compliance to the study procedures or who are otherwise not appropriate to include in this clinical trial.

18. Patients presenting contraindications to the rescue product, according to concerning Summary of Product Characteristics (SPC).

Related Conditions & MeSH terms

• Atrophy
• Vulvovaginal Atrophy

Intervention

Device:
• Celegyn®
Medical device Celegyn® presents itself as a cream.
• Matching placebo
IP placebo presents itself as a cream.

Locations

Country	Name	City	State
Italy	Spedali Civili di Brescia	Brescia
Italy	Istituto Europeo di Oncologia	Milan
Italy	Fondazione IRCCS Policlinico San Matteo	Pavia

Sponsors (2)

Lead Sponsor	Collaborator
Nathura S.p.A	Evidilya S.r.l.

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of Vaginal Health Index (VHI)	comparison between groups, mean change from Day 0 to Day 21	from Day 0 to Day 21
Secondary	Assessment of vulvar signs of VVA assessed by means of vulvoscopy	comparison between groups, mean change from Day 0 to Day 21	from Day 0 to Day 21
Secondary	Assessment of vulvar signs of VVA (vaginal secretions, vaginal epithelial integrity, vaginal epithelial surface thickness and vaginal colour, categorized as none, mild, moderate, or severe corresponding to a score of 0, 1, 2 or 3, respectively)	comparison between groups, mean change from Day 0 to Day 21	from Day 0 to Day 21
Secondary	Assessment of visible skin signs of irritation such as redness, dryness, scaling, peeling, bumps, hives, categorized as none, mild, moderate, or severe corresponding to a score of 0, 1, 2 or 3, respectively	comparison between groups, mean change from Day 0 to Day 21	from Day 0 to Day 21
Secondary	Assessment done by Investigator of overall improvement by means of Global Assessment of Improvement (GAI - according to a 7-grade scoring system, 0-6)	comparison between groups, at Day 21	at Day 21
Secondary	Assessment of subjective vaginal symptoms related to VVA and irritation (dryness, dyspareunia, burning, itching, stinging) by means of 100 mm Visual Analogue Scales	comparison between groups, mean change from Day 0 to Day 21	from Day 0 to 21
Secondary	Assessment of global severity score for symptoms of VVA	comparison between groups, mean change from Day 0 to Day 21	from Day 0 to Day 21
Secondary	Assessment of dyspareunia by means of the Marinoff Dyspareunia Scale	comparison between groups, mean change from Day 0 to Day 21	from Day 0 to Day 21
Secondary	Assessment of pain through the short form of McGill Pain questionnaire	comparison between groups, mean change from Day 0 to Day 21	from Day 0 to Day 21
Secondary	Assessment of patient satisfaction, assessed on 0 to 10 points scale (extremely dissatisfied = 0; extremely satisfied = 10)	comparison between groups, at Day 21	at Day 21
Secondary	Patient willingness to use the product in the future, assessed on 1 - 4 points scale (strongly disagree=1, disagree=2, agree=3, strongly agree=4)	comparison between groups, at Day 21	at Day 21
Secondary	Assessment of rescue product use (starting date and number of times the rescue product was used)	comparison among groups, at Day 21	at Day 21